TABLE 3

Model-based assessment of effect of normalizationa

PnUnadjustedNormalizedVariability reduction (%)
Result for variance component:% CVResult for variance component:% CV
LabSample × LabRun(Lab)Sample × Run(Lab)LabSample × LabRun(Lab)Sample × Run(Lab)
10.24560.34240.01030.06311260.00000.30990.01960.06468740
30.28480.20320.01970.06871140.04570.17290.01800.07357546
40.30460.39750.02180.06321430.02900.43740.01350.069611030
50.14370.15110.00960.0480810.02000.12360.01350.05725939
6A0.10880.26060.03040.09001010.01850.28100.00960.09418918
6B0.21770.32470.02440.05781200.02510.37740.02900.065710220
7F0.60620.07500.02080.07811420.05740.08970.01980.11136964
9V0.07020.30270.05010.07711030.03100.25940.03150.10109215
140.15150.04510.02860.0465680.02750.04270.00730.04914353
18C0.90210.37570.03980.10142290.17260.54000.02320.099914941
19A1.14790.19700.02820.05012300.11440.34570.01130.094011260
19F0.42910.19880.02970.06811340.17360.17900.02210.08409737
23F0.46490.95840.02990.07392440.06730.92150.00720.066618030
  • a The overall reduction in variability due to normalization is shown for each serotype. Estimates of the various variance components and CVs of the unadjusted and normalized results from the ANOVA are also shown. Pn, pneumococcal serotype; CV, coefficient of variation (expressed as a percent); Lab, variability among the laboratories; Run(Lab), variability among runs within each laboratory; Sample × Lab, variability associated with the interaction between test sample and laboratory; Sample × Run(Lab), variability associated with the interaction between test sample and runs within a laboratory.